OncoMatch/Clinical Trials/NCT07746713
A Study of JNJ-98768111 in Participants With Advanced Prostate Cancer
Is NCT07746713 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies JNJ-98768111 for prostatic neoplasms.
Treatment: JNJ-98768111 — The purpose of Part 1 of this study is to find out how safe JNJ-98768111 is and the most suitable dose (recommended phase 2 dose \[RP2D\]) regimen(s) of JNJ-98768111. The purpose of Part 2 of this study is to find out how safe JNJ-98768111 is at the RP2D regimen(s) in participants with advanced prostate cancer (cancer of the prostate, a male reproductive gland found below the bladder, which has spread extensively to other parts of the body).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: androgen receptor-targeted therapy
Prior treatment with at least 1 prior novel androgen receptor (AR)-targeted therapy.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Florida Cancer Specialists & Research Institute · Sarasota, Florida
- Start Midwest · Grand Rapids, Michigan
- START Mountain Region · West Valley City, Utah
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07746713 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received androgen receptor-targeted therapy.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages